Ritonavir
As of the edition of 20 October 2026, Ritonavir is a small molecule: marketed, first approved in 1996 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Norvir
- First approved
- 1 March 1996 (US)
- Approvals on record
- 28 in 5 regions
- Holder of the most recent approval
- Pfizer; 6 holders in all
- Withdrawn from market
- 25 September 2024 (in some regions)
- Registered trials
- 641, 71 stopped early
- Disease areas
- Infections; Urinary and reproductive; Immune system; Digestive system; Lungs and airways; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 95 | 74 | 0 | 11 |
| Phase 1 | 183 | 163 | 2 | 12 |
| Phase 2 | 153 | 122 | 4 | 19 |
| Phase 3 | 123 | 96 | 4 | 14 |
| Phase 4 | 87 | 57 | 1 | 15 |
| All trials | 641 |